Переход от терапии против CD20 к фумаратам в качестве стратегии лечения: многоцентральный, ретроспективный опыт наблюдений.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vollmer Brandi L, Hoyt Tammy, West Timothy W, Gutman Josef, Benitez Monica, Riddle Evan L, Lewin James B, Mendoza Jason P, Alvarez Enrique
Аннотация
Оригинал публикации
Transition from anti-CD20 therapies to fumarates as a treatment strategy: A multicenter, retrospective observational experience.
We present real-world data on patients switching from anti-CD20s to fumarates for various motivations in this retrospective observational study of 43 patients from three multiple sclerosis centers. Recurrent infections on anti-CD20s were the most common reason for switching to fumarates. Patients experienced limited disease activity on fumarates (83.7% were free from relapse and new MRI lesions), suggesting effectiveness was maintained. Of the 16.3% with disease activity on fumarates, 57.1% also had disease activity on anti-CD20s. Tolerability was the main reason for discontinuing fumarates. Future studies will provide additional insight into how to effectively and safely transition from anti-CD20s to fumarates.